SCHEMBL132858

SCHEMBL132858

Nc1ccc(N2CCC(CC(=O)O)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.53
GFER P55789 4/20 0.49
CASP6 P55212 1/20 0.49
FFAR1 O14842 1/20 0.46
MAPT P10636 4/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 3/20 0.44
ALDH1A1 P00352 3/20 0.44
USP2 O75604 2/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15650145 0.87 GFER (0.49) FFAR4GFERCASP6MAPTKDM4E
SCHEMBL25845505 0.86 GFER (0.55) FFAR4GFERCASP6MAPTKDM4E
SCHEMBL2557268 0.85 FFAR4 (0.61) FFAR4FFAR1MAPTNPSR1L3MBTL1
SCHEMBL15651683 0.84 GFER (0.46) FFAR4GFERCASP6MAPTKDM4E
SCHEMBL26373077 0.84 FFAR4 (0.55) FFAR4FFAR1MAPTUSP2HTT
SCHEMBL20271745 0.84 NOTUM (0.56) FFAR4MAPTKDM4EALDH1A1NPC1
SCHEMBL20271742 0.84 NOTUM (0.56) FFAR4FFAR1ALDH1A1HTTITGB3
SCHEMBL15652238 0.82 SYK (0.51) FFAR4GFERCASP6MAPTKDM4E
SCHEMBL13114895 0.82 GFER (0.48) GFERCASP6MAPTKDM4EGAA
SCHEMBL3770035 0.81 USP2 (0.53) FFAR4MAPTALDH1A1USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4327886-A2 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF Libertas Bio, Inc. (US) 2024-02-28 EP disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
EP-2748166-B1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF ASANA BIOSCIENCES LLC (US) 2018-07-11 EP disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
US-8772494-B2 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b JANSSEN PHARMACEUTICA N.V. (BE) 2014-07-08 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
EP-1694644-B1 N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B JANSSEN PHARMACEUTICA NV (BE) 2012-03-07 EP disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed
US-20070099934-A1 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
EP-1694644-A2 N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B JANSSEN PHARMACEUTICA N.V. (BE) 2006-08-30 EP disclosed
WO-2005058824-A2 N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTE IN B JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK FFAR4 4147/4885GFER 3828/4885CASP6 3379/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK FFAR4 4295/4885GFER 4102/4885CASP6 3453/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK FFAR4 4147/4885GFER 3828/4885CASP6 3379/4885
US-20070099934-A1 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b APOB, PNLIP, LIPC FFAR4 240/4885GFER 2606/4885CASP6 2430/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK FFAR4 4112/4885GFER 3792/4885CASP6 3264/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK FFAR4 4112/4885GFER 3792/4885CASP6 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.